New hope for rare kidney disease patients through early access program
NCT ID NCT04729062
Summary
This program provides early access to an investigational drug called pegcetacoplan for patients with rare kidney diseases C3G or IC-MPGN. It's for people aged 12+ who haven't responded well to other treatments and have active kidney disease. Participants must be able to self-administer the medication or have a caregiver who can help.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.